(AOF) – Sanofi announces that frexalimab, its experimental antibody against multiple sclerosis (MS), achieved a sustained reduction in disease activity and displayed favorable tolerability after one year of treatment in the from a clinical trial, in participants with relapsing-remitting multiple sclerosis. These results will be presented today at the 2024 Annual Meeting of the American Academy of Neurology (AAN), being held in Denver, Colorado, USA.
For the group, this product “has the potential to be the first in its pharmacotherapeutic class for the treatment of relapsing-remitting multiple sclerosis”.
Sanofi has initiated international phase III clinical trials of frexalimab for the treatment of relapsing-remitting MS and secondary progressive MS.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.